Capsule Summary Slides

Share

Program Content

Activities

  • Glofitamab in R/R LBCL
    Extended Follow-up and Landmark Analyses From Pivotal Phase II Trial of Glofitamab in R/R LBCL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2023

  • COMMANDS
    COMMANDS: Luspatercept vs Epoetin alfa for ESA-Naive Transfusion-Dependent Lower-Risk MDS
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2023

  • IMerge
    IMerge: Phase III Trial of Imetelstat vs Placebo for Transfusion-Dependent Lower-Risk MDS Relapsed/Refractory to ESAs
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2023

  • Elranatamab After BCMA Therapy in R/R MM
    Elranatamab Monotherapy for R/R MM After Previous BCMA-Directed Therapy: Pooled Analysis of MagnetisMM Studies
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2023

  • Phase I PHE885 CAR T-Cell
    Phase I: BCMA-Targeted PHE885 CAR T-Cell Therapy With Rapid Manufacturing Time for R/R Multiple Myeloma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • MajesTEC-1 Update: Teclistamab in R/R MM
    MajesTEC-1 Update: Phase I/II Study of Teclistamab in Patients With R/R MM
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • CPX-351 vs 7+3: Cardiotoxicity
    Cardiotoxicity of CPX-351 vs 7+3 in Previously Untreated High-Risk or Secondary AML: Post Hoc Analysis of a Pivotal Phase III Trial
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • JACKPOT8
    JACKPOT8 Part B: Pivotal Phase II Study of Golidocitinib, a JAK1-Selective Inhibitor, in Relapsed/Refractory PTCL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • EPCORE NHL-1 Update
    EPCORE NHL-1 Update: Pivotal Phase I/II Trial of Epcoritamab in Patients With R/R B-Cell NHL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • KEYNOTE-667
    KEYNOTE-667 High-Risk Group Update: Pembrolizumab + COPDAC-28 Consolidation in Children and AYA cHL
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • BRUIN 2-Yr Update
    BRUIN 2-Yr Update: Phase I/II Trial Evaluating Pirtobrutinib in Covalent BTKi–Treated MCL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • CARTITUDE-1 Update
    CARTITUDE-1 Update: Phase I/II Trial of Ciltacabtagene Autoleucel for Heavily Pretreated Relapsed/Refractory Multiple Myeloma
    Capsule Summary
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • Alliance A041703
    Alliance A041703: Phase II Trial of Inotuzumab Ozogamicin Induction Followed by Blinatumomab Consolidation for Older Adults With Newly Diagnosed Ph-Negative, CD22-Positive B-ALL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2023

  • TRANSCEND CLL 004
    TRANSCEND CLL 004: Phase I/II Trial of Lisocabtagene Maraleucel for Relapsed/Refractory CLL/SLL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2023

  • SWOG S1826
    SWOG S1826: Phase III Trial of Nivolumab + AVD vs Brentuximab Vedotin + AVD for Newly Diagnosed Advanced cHL
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2023

  • CARTITUDE-4 With Cilta-Cel vs SoC
    CARTITUDE-4: Phase III Trial of Ciltacabtagene Autoleucel vs SoC for Lenalidomide-Refractory Multiple Myeloma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 12, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis